Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lessened its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 37.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,542 shares of the company's stock after selling 102,565 shares during the period. Two Sigma Investments LP owned 0.31% of Fulcrum Therapeutics worth $797,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at approximately $38,000. Mariner LLC acquired a new stake in Fulcrum Therapeutics during the 4th quarter worth approximately $78,000. Cantor Fitzgerald L. P. acquired a new stake in Fulcrum Therapeutics during the 4th quarter worth approximately $94,000. Zacks Investment Management acquired a new stake in Fulcrum Therapeutics during the 4th quarter worth approximately $99,000. Finally, Intech Investment Management LLC lifted its holdings in Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock worth $143,000 after buying an additional 13,057 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Up 2.0%

FULC stock opened at $7.25 on Friday. The company has a market cap of $391.35 million, a price-to-earnings ratio of -23.39 and a beta of 2.29. The business has a fifty day simple moving average of $4.80 and a 200-day simple moving average of $4.16. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. As a group, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FULC has been the topic of several recent analyst reports. HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a report on Thursday, May 15th. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, May 23rd. Finally, Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the company from $4.00 to $12.00 in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Fulcrum Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $6.29.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.